<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        58-370-15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VIVARO 100 IU/ml pre-filled pen, disposable
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        INSULIN GLARGINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        216.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="sanofi-aventis" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            sanofi-aventis
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10AE04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vivaro is a clear, colorless solution for injection containing insulin glargine. Insulin glargine is a modified insulin, very similar to human insulin. It is made by a biotechnology process. Insulin glargine has a long and steady blood-sugar-lowering action.</p><p>Vivaro is used to reduce high blood sugar in adults, adolescents and children of 6 years or above with diabetes mellitus. Diabetes mellitus is a disease where your body does not produce enough Insulin to control the level of blood sugar.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Vivaro</p><p>If you are allergic (hypersensitive) to insulin glargine or to any of the other ingredients of Vivaro.</p><p><strong>Take special care with Vivaro</strong></p><p>Follow closely the instructions for dosage, monitoring (blood and urine tests), diet and physical activity (physical work and exercise). Injection technique as discussed with your doctor.</p><p><strong>Special patient groups</strong></p><p>There is limited experience with the use of Vivaro in children less than 6 years old and in patients whose liver or kidneys do not function well.</p><p><strong>Travel</strong></p><p>Before travelling consult your doctor. You may need to talk about</p><p>- the availability of your insulin in the country you are visiting,</p><p>- supplies of insulin, syringes etc,</p><p>- correct storage of your insulin while travelling,</p><p>-timing of meals and insulin administration while travelling,</p><p>- the possible effects of changing to different time zones,</p><p>- possible new health risks in the countries to be visited,</p><p>- what you should do in emergency situations when you feel unwell or become ill.</p><p><strong>Illnesses and Injuries</strong></p><p>In the following situations, the management of your diabetes may require a lot of care:</p><p>If you are ill or have a major injury, then your blood sugar level may increase (hyperglycemia).</p><p>If you are not eating enough your blood sugar level may become too low (hypoglycemia).</p><p>In most cases you will need a doctor. Make sure that you contact a doctor early.</p><p>If you have type 1 diabetes (insulin dependent diabetes mellitus), do not stop your insulin and continue to get enough carbohydrates. Always tell people who are caring for you or treating you that you require insulin.</p><p><strong>Using other medicines</strong></p><p>Some medicines cause changes in the blood sugar level (decrease, increase or both depending on the situation). In each case, it may be necessary to adjust your Insulin dosage to avoid blood sugar levels that are either too low or too high. Be careful when you start or stop taking another medicine.</p><p>Tell your doctor about all medicines that you are taking, including those you have bought without a prescription. Before taking a medicine ask your doctor if it can affect your blood sugar level and what action, if any, you need to take.</p><p>Medicines that may cause your blood sugar level to fall (hypoglycemia) include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; all other medicines to treat diabetes,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; disopyramide (used to treat certain heart conditions),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; fluoxetine (used to treat depression),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; fibrates (used to lower high levels of blood lipids),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; monoamine oxidase (MAO) inhibitors (used to treat depression),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; pentoxifylline, propoxyphene, salicylates (such as aspirin, used to relieve pain and lower fever),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; sulfonamide antibiotics.</p><p><strong>Medicines that may cause your blood sugar level to rise (hyperglycaemia) include:</strong></p><p>-&nbsp;&nbsp; corticosteroids (such as &quot;cortisone&quot; used to treat inflammation),</p><p>-&nbsp;&nbsp; danazol (medicine acting on ovulation),</p><p>-&nbsp;&nbsp; diazoxide (used to treat high blood pressure),</p><p>-&nbsp;&nbsp; diuretics (used to treat high blood pressure or excessive fluid retention),</p><p>-&nbsp;&nbsp; glucagon (pancreas hormone used to treat severe hypoglycaemia),</p><p>-&nbsp;&nbsp; isoniazid (used to treat tuberculosis),</p><p>-&nbsp;&nbsp; oestrogens and progestagens (such as in the contraceptive pill used for birth control),</p><p>-&nbsp;&nbsp; phenothiazine derivatives (used to treat psychiatric disorders),</p><p>-&nbsp;&nbsp; somatropin (growth hormone),</p><p>-&nbsp;&nbsp; sympathomimetic medicines (such as epinephrine [adrenaline], or salbutamol, terbutallne used to treat asthma),</p><p>-&nbsp; thyroid hormones (used to treat thyroid gland disorders),</p><p>-&nbsp; atypical antipsychotic medications (such as clozapine, olanzapine),</p><p>-&nbsp;&nbsp; protease inhibitors (used to treat HIV).</p><p><strong>Your blood sugar level may either rise or fall if you take:</strong></p><p>-&nbsp;&nbsp; beta-blockers (used to treat high blood pressure),</p><p>-&nbsp;&nbsp; clonidine (used to treat high blood pressure),</p><p>-&nbsp;&nbsp; lithium salts (used to treat psychiatric disorders).</p><p>-&nbsp;&nbsp; Pentamidine (used to treat some infections caused by parasites) may cause hypoglycaemia which may sometimes be followed by hyperglycaemia. Beta-blockers like other sympatholytic medicines (such as clonidine, guanethidine, and reserpine) may weaken or suppress entirely the first warning symptoms which help you to recognize a hypoglycaemia.</p><p>If you are not sure whether you are taking one of those medicines, ask your doctor or pharmacist</p><p><strong>Using Vivaro with food and drink</strong></p><p>Your blood sugar levels may either rise or fall if you drink alcohol.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>Inform you r doctor if you are planning to become pregnant, or if you are already pregnant. Your insulin dosage may need to be changed during pregnancy and after giving birth. Particularly careful control of your diabetes, and prevention of hypoglycaemia, is important for the health of your baby.</p><p>If you are breast-feeding consult your doctor as you may require adjustments in your insulin doses and your diet.</p><p><strong>Driving and using machines</strong></p><p>Your ability to concentrate or react may be reduced if:</p><p>-you have hypoglycaemia (low blood sugar levels),</p><p>-you have hyperglycaemia (high blood sugar levels),</p><p>-you have problems with your sight.</p><p>Keep this possible problem in mind in all situations where you might put yourself and others at risk (such as driving a car or operating machinery).</p><p><strong>You should contact your doctor for advice on driving If:</strong></p><p>-You have frequent episodes of hypoglycaemia,</p><p>-the first warning symptoms which help you to recognise hypoglycaemia are reduced or absent.</p><p>Important information about some of the ingredients of Vivaro</p><p>This medicinal product contains less than 1 mmol (23 mg) sodium per dose, i.e. it is essentially&#39;sodium-free&#39;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Dosage</strong></p><p>Based on your life-style and the results of your blood sugar (glucose) tests and your previous insulin usage, your doctor will</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; determine how much Vivaro per day you will need and at what time.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; tell you when to check your blood sugar level, and whether you need to carry out urine tests,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; tell you when you may need to inject a higher or lower dose of Vivaro.</p><p>Vivaro is a long-acting insulin. Your doctor may tell you to use it in combination with a short-acting insulin or with tablets used to treat high blood sugar levels.</p><p>Many factors may Influence your blood sugar level. You should know these factors so that you are able to react correctly to changes in your blood sugar level and to prevent it from becoming too high or too low. Seethe box at the end of this leaflet for further information.</p><p><strong>Frequency of administration</strong></p><p>You need one injection of Vivaro every day, at the same time of the day.</p><p>In children, only evening injection has been studied.</p><p><strong>Method of administration</strong></p><p>Vivaro is injected under the skin. Do NOT inject Vivaro in a vein, since this will change its action and may cause hypoglycaemia.</p><p>Your doctor will show you in which area of the skin you should inject Vivaro. With each injection, change the puncture site within the particular area of skin that you are using.</p><p><strong>How to handle Vivaro Pen</strong></p><p>Vivaro Pen is a pre-filled disposable pen containing insulin glargine.</p><p><strong>Read carefully the &ldquo;Vivaro Pen Instructions for Use<sup>,r</sup> Included In this package leaflet You must use the pen as described in these Instructions for Use.</strong></p><p>A new needle must be attached before each use. Only use needles that are compatible for use with Vivaro Pen (see &ldquo;Vivaro Pen Instructions for Use&quot;).</p><p>A safety test must be performed before each injection.</p><p>Look at the cartridge before you use the pen. Do not use Vivaro Pen if you notice particles in it Only use Vivaro Pen if the solution is clear, colorless and water like. Do not shake or mix it before use.</p><p>To prevent the possible transmission of disease, each pen must be used by one patient only.</p><p>Make sure that neither alcohol nor other disinfectants or other substances contaminate the Insulin.</p><p>Always use a new pen if you notice that your blood sugar control is unexpectedly getting worse. If you think you may have a problem with Vivaro Pen, consult your Health Care Professional.</p><p>Empty pens must not be re-filled and must be properly discarded.</p><p>Do not use Vivaro Pen if it is damaged or networking properly, it has to be discarded and a new Vivaro Pen has to be used.</p><p><strong>Mistakes in dosage If you use more Vivaro than you should</strong></p><p>- If you have injected too much Vivaro, your blood sugar level may become too low (hypoglycaemia). Check</p><p>your blood sugar frequently. In general, to prevent hypoglycaemia you must eat more food and monitor your lood sugar. For information on the treatment of hypoglycaemia, see box at the end of this leaflet.</p><p>If you forget to use Vivaro</p><p>- If you have missed a dose of Vivaro or if you have not injected enough insulin, your blood sugar level may become too high (hyperglycaemia). Check your blood sugar frequently. For information on the treatment of hyperglycaemia, see box at the end of this leaflet.</p><p>- Do not take a double dose to make up for a forgotten dose.</p><p>If you 3top using Vivaro</p><p>This could lead to severe hyperglycaemia (very high blood sugar) and ketoacidosis (build-up of acid in the blood because the body is breaking down fat instead of sugar). Do not stop Vivaro without speaking to a doctor, who will tell you what needs to be done.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Vivaro can cause side effects, although not everybody gets them.</p><p>Hypoglycaemia (low blood sugar) can be very serious. If your blood sugar level falls too much you may become unconscious. Serious hypoglycaemia may cause brain damage and may be life-threatening. If you have symptoms of low blood sugar, take actions to increase your blood sugar level immediately.</p><p>If you experience the following symptoms, contact your doctor immediately:</p><p>large-scale skin reactions (rash and itching all over the body), severe swelling of skin or mucous membranes (angiooedema), shortness of breath, a fall in blood pressure with rapid heartbeat and sweating. These could be symptoms of severe allergic reactions to insulins and may become life-threatening.</p><p><strong>Very common reported side effects </strong></p><p>(experienced in more than 1 in 10 patients)</p><p><strong>&bull; Hypoglycaemia</strong></p><p>As with all insulin therapy, the most frequent side effect is hypoglycaemia.</p><p>Hypoglycaemia (low blood sugar) means that there is not enough sugar in the blood. For further information on the side effects of low blood sugar or high blood sugar, see the box at the end of this leaflet.</p><p>Common reported side effects</p><p>(experienced in more than 1 in 100 but less than 1 in 10 patients)</p><p><strong>&bull; Skin changes at the Injection site (lipodydtrophy)</strong></p><p>If you inject your insulin too often at the same skin site, Fetty tissue under the skin at this site may either shrink or thicken. Thickening of fatty tissue may occur in 1 to 2% of patients while shrinking may occur uncommonly. Insulin that you inject in such a site may not work very well. Changing the injection site with each Injection may help to prevent such skin changes.</p><p><strong>&bull; Skin and allergic reactions</strong></p><p>(3 to 4) % of patients may experience reactions at the injection site (such as reddening, unusually intense pain on injection, itching, hives, swelling or inflammation). They can also spread around the injection site. Most minor reactions to insulins usually resolve in a few days to a few weeks.</p><p><strong>Rare reported side effect </strong>(experienced in more than 1<strong> </strong>in <strong>10,000 </strong>but less than 1<strong> </strong>in <strong>1,000 </strong>patients)</p><p><strong>&bull; Severe allergic reactions to Insulins</strong></p><p>Associated symptoms may include large-scale skin reactions (rash and itching all over the body), severe swelling of skin or mucous membranes (angiooedema), shortness of breath, a fall in blood pressure with rapid heartbeat and sweating. These could be symptoms of <strong>severe allergic reactions to insulins and may become life-threatening.</strong></p><p><strong>&bull; Eye reactions</strong></p><p>A marked change (improvement or worsening) in your blood sugar control can disturb your vision temporarily. If you have proliferative retinopathy (an eye disease related to diabetes) severe hypoglycaemic attacks may cause temporary loss of vision.</p><p><strong>Other side effects include:</strong></p><p>Insulin treatment can cause the body to produce antibodies to insulin (substances that act against insulin). Rarely, this may require a change to your insulin dosage.</p><p>In rare cases, insulin treatment may also cause temporary build-up of water in the body, with swelling in the calves and ankles.</p><p>In very rare cases, dysgeusia (taste disorders) and myalgia (muscular pain) can occur.</p><p><strong>Paediatric patients</strong></p><p>In general, the side effects in patients of 18 years of age or less are similar to those seen in adults.</p><p>Complaints of injection site reactions and skin reactions are reported relatively more frequently in patients of 18 years of age or less than in adult patients.</p><p>No clinical study safety data are available in patients below 6 years of age.</p><p>Tell your doctor or pharmacist if you notice any of the side effects listed above or any other unwanted or unexpected effects. To prevent serious reactions, speak to a doctor immediately if a side effect is severe, occurs suddenly or gets worse rapidly.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not use Vivaro after the expiry date which is stated on the carton and on the label of the pen. The expiry date refers to the last day of that month.</p><p>Not in-use pens</p><p>Store in a refrigerator (2 &deg;C-8 &deg;C). Do not freeze. Do not put Vivaro Pen next to the freezer compartment or a freezer pack.</p><p>Keep the pre-filled pen in the outer carton in order to protect from light.</p><p>In use pens</p><p>Pre-filled pens in use or carried as a spare may be stored for a maximum of 4 weeks not above 25&deg;C away from direct heat or direct light the pen in use must not be stored in the refrigerator. Do not use it after this time period.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-The active substance is Insulin glargine.</p><p>One milliliter of the solution contains 100 Units of the active substance insulin glargine.</p><p>- Other ingredients are: zinc chloride, m-cresol, glycerol, sodium hydroxide, hydrochloric acid and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Vivaro 100 Units/ml solution for injection in a pre-filled pen 
Each pen contains 3ml solution (300 Units).
Each box contains 5 pens

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>SAJA Pharmaceuticals </strong></p><p><strong>Manufacturer by</strong></p><p>Sanofi-Aventis Deutschland GmbH D-65926 Frankfurt am Main, Germany</p><p>For Saudi Arabian Japanese Pharmaceutical</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Dec/2015
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">فيفارو هو محلول للحقن صاف وعديم اللون يحتوي على الأنسولين &quot;جلارجين&quot;. الأنسولين &quot;جلارجين&quot; هو أنسولين معدل، يشبه إلى حد كبير الأنسولين البشري. ويتم ذلك من خلال عملية تقنية حيية. ولدى الأنسولين جلارجين تأثير خافض لمستوى السكر في الدم ثابت وطويل المدى.</p><p dir="RTL">يُستخدم فيفارو لخفض سكر الدم المرتفع في البالغين والمراهقين والأطفال البالغين من العمر 6 سنوات أو أكثر الذي يعانون من مرض السكري. مرض السكري هو مرض لا ينتج فيه الجسم ما يكفي من الأنسولين للتحكم في مستوى السكر في الدم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم فيفارو في ما يلي:</strong></p><p dir="RTL">إذا كنت تعاني من حساسية (فرط حساسية) تجاه الأنسولين &quot;جلارجين&quot; أو أيّ من المكونات الأخرى لفيفارو.</p><p dir="RTL"><strong>توخ حذرًا خاصًّا مع فيفارو فيما يلي:</strong></p><p dir="RTL">اتبع بعناية تعليمات الجرعة والمراقبة (اختبارات الدم والبول)، والنظام الغذائي والنشاط البدني (العمل البدني والتمارين الرياضية)، وتقنية الحقن كما تمت مناقشتها مع طبيبك.</p><p dir="RTL"><strong>المجموعات الخاصة من المرضى</strong></p><p dir="RTL">هناك تجربة محدودة لاستخدام فيفارو في الأطفال أقل من 6 سنوات والمرضى الذي يعانون من قصور في وظائف الكبد أو الكلى.</p><p dir="RTL">السفر</p><p dir="RTL">استشر طبيبك قبل السفر. فقد تحتاج إلى التحدث عما يلي:</p><p dir="RTL">- توافر الأنسولين الخاص بك في البلد الذي تقوم بزيارته،</p><p dir="RTL">- مخزونك من الأنسولين والحقن وغيرها،</p><p dir="RTL">- تخزين الأنسولين الخاص بك بشكل سليم أثناء السفر،</p><p dir="RTL">- توقيت تناول الوجبات والأنسولين أثناء السفر،</p><p dir="RTL">- الأعراض المحتملة نتيجة الانتقال إلى مناطق زمنية مختلفة،</p><p dir="RTL">- المخاطر الصحية الجديدة المحتملة في البلدان التي ستتم زيارتها،</p><p dir="RTL">ما يجب عليك القيام به في حالات الطوارئ عندما تشعر بالإعياء أو حين تمرض.</p><p dir="RTL">الأمراض والإصابات</p><p dir="RTL">قد يتطلب مرض السكري الخاص بك الكثير من الرعاية في الحالات الآتية:</p><p dir="RTL">إذا كنت مريضًا أو كنت تعاني من إصابة كبرى عندئذٍ قد يرتفع مستوى السكر لديك في الدم (فرط سكر الدم).</p><p dir="RTL">إذا كنت لا تأكل بما فيه الكفاية قد يصبح مستوى السكر لديك في الدم منخفضًا للغاية (نقص سكر الدم).</p><p dir="RTL">في معظم الحالات سوف تحتاج إلى طبيب. احرص على الاتصال بطبيب في وقت مبكر.</p><p dir="RTL">إذا كنت تعاني من مرض السكري من النوع &quot;1&quot; (مرض السكري المعتمد على الأنسولين)، لا توقف الأنسولين واستمر في الحصول على ما يكفي من الكربوهيدرات. أخبر دائمًا الأشخاص الذين يقومون برعايتك أو علاجك إنك تحتاج إلى الأنسولين.</p><p dir="RTL"><strong>استخدام أدوية أخرى</strong></p><p dir="RTL">تؤدي بعض الأدوية إلى تغيرات في مستوى السكر في الدم (انخفاض، زيادة أو كليهما حسب الحالة). في كل حالة، قد يكون من الضروري تعديل جرعة الأنسولين الخاصة بك لتجنب مستويات السكر في الدم التي إما أن تكون منخفضة جدًا أو مرتفعة جدًا، توخي الحذر عند بدء أو وقف تناول دواء آخر.</p><p dir="RTL">أخبر طبيبك عن جميع الأدوية التي تتناولها، بما في ذلك تلك التي اشتريتها بدون وصفة طبية. قبل تناول أي دواء اسأل طبيبك إذا كان يمكن أن يؤثر على مستوى السكر في الدم لديك، وما هي الإجراءات التي تحتاج إلى اتخاذها، إن وجدت.</p><p dir="RTL">تشمل الأدوية التي قد تؤدي إلى انخفاض مستوى السكر في الدم (نقص سكر الدم) ما يلي:</p><p dir="RTL">- جميع أدوية علاج مرض السكري الأخرى،</p><p dir="RTL">- مثبطات الإنزيم المحول للأنجيوتنسين &quot;ACE&quot; (تستخدم لعلاج بعض أمراض القلب أو ارتفاع ضغط الدم)،</p><p dir="RTL">- ديسوبيراميد (يُستخدم لعلاج بعض أمراض القلب)،</p><p dir="RTL">- فلوكستين (يُستخدم لعلاج الاكتئاب)،</p><p dir="RTL">- فيبرات (تستخدم لخفض المستويات المرتفعة للدهون في الدم)،</p><p dir="RTL">- مثبطات أكسيداز أحادي الأمين &quot;MAO&quot; (تستخدم لعلاج الاكتئاب)،</p><p dir="RTL">- بنتوكسيفيلين، وبروبوكسيفين، والساليسيلات (مثل الأسبرين، الذي يُستخدم لتخفيف الآلام وخفض الحمى)،</p><p dir="RTL">- المضادات الحيوية من فئة سلفوناميد.</p><p dir="RTL">تشمل الأدوية التي قد تؤدي إلى ارتفاع مستوى السكر في الدم (فرط سكر الدم) ما يلي:</p><p dir="RTL">- الكورتيكوستيرويدات (مثل &quot;الكورتيزون&quot; الذي يُستخدم لعلاج الالتهاب)،</p><p dir="RTL">- دانازول (دواء يؤثر على عملية التبويض)،</p><p dir="RTL">- ديازوكسيد (يُستخدم لعلاج ارتفاع ضغط الدم)،</p><p dir="RTL">- مدرات البول (تستخدم لعلاج ارتفاع ضغط الدم أو فرط احتباس السوائل)،</p><p dir="RTL">- الجلوكاجون (هرمون يفرزه البنكرياس، يُستخدم لعلاج نقص سكر الدم الشديد)،</p><p dir="RTL">- أيزونيازيد (يُستخدم لعلاج السل)،</p><p dir="RTL">- الإستروجينات أو البروجسيتوجينات (مثل: حبوب منع الحمل التي تستخدم لتحديد النسل)،</p><p dir="RTL">- مشتقات الفينوثيازين (تستخدم لعلاج الاضطرابات النفسية)،</p><p dir="RTL">- سوماتروبين هرمون النمو)،</p><p dir="RTL">- محاكيات الودي السمبثاوي (مثل الإيبينيفرين [الأدرينالين]، أو سالبيوتامول، وتيربيوتالين التي تستخدم لعلاج الربو)،</p><p dir="RTL">- هرمونات الغدة الدرقية (تستخدم لعلاج اضطرابات الغدة الدرقية)،</p><p dir="RTL">- مضادات الذهان غير التقليدية (مثل كلوزابين، وأولانزابين)،</p><p dir="RTL">- مثبطات إنزيم البروتياز (تستخدم لعلاج العدوي بفيروس نقص المناعة البشري &quot;HIV&quot;).</p><p dir="RTL">قد يرتفع أو ينخفض مستوى السكر لديك في الدم إذا كنت تتناول ما يلي:</p><p dir="RTL">- حاصرات مستقبلات البيتا (تستخدم لعلاج ارتفاع ضغط الدم)،</p><p dir="RTL">- كلونيدين (يُستخدم لعلاج ارتفاع ضغط الدم)،</p><p dir="RTL">- أملاح الليثيوم (تستخدم لعلاج الاضطرابات النفسية)،</p><p dir="RTL">قد يؤدي بنتاميدين (يُستخدم لعلاج بعض العدوى الناتجة عن الطفيليات) إلى نقص سكر الدم الذي قد يليه في بعض الأحيان فرط سكر الدم. قد تؤدي حاصرات مستقبلات البيتا مثل الأدوية الأخرى الحالة للودي السمبثاوي (مثل كلونيدين، وجوانيثيدين، وريسيربين) إلى ضعف أو منع ظهور أعراض الإنذار الأول تمامًا، حيث تساعدك هذه الأعراض على إدراك وجود نقص سكر الدم.</p><p dir="RTL">إذا لم تكن متأكدًا ما إذا كنت تتناول إحدى هذه الأدوية اسأل الطبيب أو الصيدلي الخاص بك.</p><p dir="RTL"><strong>استخدام فيفارو مع الطعام والشراب</strong></p><p dir="RTL">قد يرتفع أو ينخفض مستوى السكر لديك في الدم إذا كنت تتناول الكحول.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">استشر الطبيب أو الصيدلي الخاص بك قبل تناول أي دواء.</p><p dir="RTL">أخبري طبيبك إذا كنت تنوين الحمل أو إذا كنت حاملاً بالفعل. قد يكون هناك حاجة لتغيير جرعة الأنسولين الخاصة بك أثناء الحمل وبعد الولادة بوجه خاص، يُعد التحكم الحذر في مرض السكري لديك، والوقاية من نقص سكر الدم، أمرًا هامًا بالنسبة لصحة طفلك.</p><p dir="RTL">إذا كنت ترضعين، استشيري طبيبك حيث أنك قد تحتاجين لإجراء تعديلات في جرعات الأنسولين الخاصة بك ونظامك الغذائي.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد تنخفض قدرتك على التركيز أو رد فعل في الحالات التالية:</p><p dir="RTL">- إذا كنت تعاني من نقص سكر الدم (انخفاض مستويات السكر في الدم)،</p><p dir="RTL">- إذا كنت تعاني من فرط سكر الدم (ارتفاع مستويات السكر في الدم)،</p><p dir="RTL">- إذا كنت تعاني من مشاكل في الرؤية.</p><p dir="RTL">ضع هذه المشكلة المحتملة في الاعتبار في جميع الحالات التي قد تعرض فيها نفسك والآخرين للخطر (مثل قيادة السيارة أو تشغيل الآلات). يجب عليك الاتصال بطبيبك للحصول على المشورة بشأن القيادة في الحالات التالية:</p><p dir="RTL">- إذا كنت تعاني من نوبات متكررة من نقص سكر الدم،</p><p dir="RTL">- إذا كانت أعراض الإنذار الأول، التي تساعدك على إدراك وجود نقص سكر الدم، منخفضة أو غائبة.</p><p dir="RTL">معلومات هامة عن بعض مكونات فيفارو</p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مللي مول (23 مجم) صوديوم للجرعة الواحدة، أي يُعد &quot;خالي من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الجرعة</p><p dir="RTL">استنادًا إلى نمط حياتك ونتائج اختبارات السكر في الدم (الجلوكوز) الخاصة بك واستخدامك السابق للأنسولين، سيقوم طبيبك بالآتي:</p><p dir="RTL">- تحديد مقدار ما ستحتاج إليه يوميًا من فيفارو وفي أي وقت.</p><p dir="RTL">- إخبارك متى تفحص مستوى السكر لديك في الدم، وإذا كنت في حاجة إلى إجراء اختبارات بول،</p><p dir="RTL">- إخبارك متى قد تحتاج إلى حقن جرعة أعلى أو أقل من فيفارو.</p><p dir="RTL">فيفارو هو أنسولين طويل المفعول. قد يقول لك طبيبك أن تستخدمه مع الأنسولين قصير المفعول أو مع الأقراص المستخدمة لعلاج ارتفاع مستويات السكر في الدم. قد تؤثر عدة عوامل على مستوى السكر لديك في الدم. يجب عليك معرفة هذه العوامل لكي تكون قادرًا على التصرف بشكل سليم مع تغيرات مستوى السكر لديك في الدم ومنعه من الانخفاض أو الارتفاع الشديد. لمزيد من المعلمات انظر الإطار في نهاية هذه النشرة.</p><p dir="RTL">تكرار التناول</p><p dir="RTL">تحتاج إلى حقنة واحدة من فيفارو كل يوم، في نفس الوقت من اليوم.</p><p dir="RTL">في الأطفال، تم دراسة الحقن المسائي فقط.</p><p dir="RTL">طريقة التناول</p><p dir="RTL">يتم حقن فيفارو أسفل الجلد، لا تحقن فيفارو في الوريد، حيث سيغير ذلك من تأثره وقد يسبب نقس سكر الدم.</p><p dir="RTL">سيُريك طبيبك في أي منطقة من الجلد يجب عليك حقن فيفارو. مع كل حقنة، قم بتغيير موضع الحقن داخل المنطقة المعينة من الجلد التي تستخدمها.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">كيفية التعامل مع قلم فيفارو</p><p dir="RTL">يُعد قلم فيفارو قلم سابق التعبئة للاستعمال مرة واحدة، يحتوي على الأنسولين &quot;جلارجين&quot;.</p><p dir="RTL">اقرأ بعناية &quot;تعليمات استخدام قلم فيفارو&quot; المدرجة في هذه النشرة الداخلية.</p><p dir="RTL">يجب عليك استخدام القلم كما هو موضع في هذه التعليمات للاستخدام.</p><p dir="RTL">يجب استخدام إبرة جديدة قبل كل استخدام. استخدم فقط الإبر التي يتوافق استخدامها مع قلم فيفارو (انظر &quot;تعليمات استخدام قلم فيفارو&quot;).</p><p dir="RTL">يجب إجراء اختبار أمان قبل كل حقن.</p><p dir="RTL">انظر إلى الخرطوشة قبل استخدام القلم. لا تستدم قلم فيفارو إذا لاحظت وجود جسيمات بداخله. لا تستخدم قلم فيفارو إلا إذا كان المحلول صافٍ وعديم اللون ويشبه الماء. لا تقم برَجُّ أو مزجه قبل الاستخدام.</p><p dir="RTL">يجب استخدام القلم من قِبَل مريض واحد فقط، من أجل الوقاية من الانتقال المُحتمَل للأمراض.</p><p dir="RTL">تأكد من عدم وجود كحول أو مطهرات أخرى أو غير ذلك من مواد تؤدي إلى تلوث الأنسولين.</p><p dir="RTL">استخدم دائمًا قلمًا جديدًا إذا لاحظت أن تحكمك في سكر الدم يسوء بشكل غير مُتوقَّع. إذا اعتقدت أنك قد تواجه مشكلة عند استخدامك قلم فيفارو، فاستشر أخصائي الرعاية الصحية الخاصة بك.</p><p dir="RTL">يجب عدم إعادة تعبئة الأقلام الفارغة كما يجب التخلص منها بشكل مناسب.</p><p dir="RTL">لا تستخدم قلم فيفارو إذا تعرض للتلف أو لم يعمل بشكل مناسب، يجب التخلص منه واستخدام قلم جديد.</p><p dir="RTL">أخطاء الجرعة؛ إذا استخدمت كمية أكثر مما يجب من فيفارو:</p><p dir="RTL">- إذا قمت بحقن كمية كبيرة من فيفارو، قد يصبح مستوى السكر لديك في الدم منخفضًا للغاية (نقس سكر الدم). تحقق من نسبة السكر لديك في الدم بشكل متكرر. بصفة عامة، للوقاية من نقص سكر الدم يجب أن تتناول المزيد من الطعام ومراقبة سكر الدم لديك. لمزيد من المعلومات حول علاج سكر الدم، انظر الإطار في نهاية هذه النشرة.</p><p dir="RTL">إذا نسيت تناوُل فيفارو</p><p dir="RTL">- إذا نسيت تناوُل جرعة من فيفارو أو لم تحقن ما يكفي من الأنسولين، فقد يصبح مستوى سكر الدم لديك مرتفعًا للغاية (فرط سكر الدم). تحقق من نسبة السكر لديك في الدم بشكل متكرر. لمزيد من المعلومات حول علاج فرط سكر الدم، انظر الإطار في نهاية هذه النشرة.</p><p dir="RTL">- لا تتناول جرعة مضاعفة لتعويض جرعة نسيتها.</p><p dir="RTL">إذا توقفت عن تناوُل فيفارو</p><p dir="RTL">قد يؤدي ذلك إلى ارتفاع شديد في سكر الدم وحماض كيتوني (تراكم الأحماض في الدم نتيجة تحطيم الجسم للدهون بدلاً من السكر). لا تتوقف عن تناوُل فيفارو دون التحدث إلى طبيب، فهو الذي بإمكانه إخبارك بما تحتاج إلى القيام به.</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا المنتج، فاستشر الطبيب أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب فيفارو أعراضًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">قد يكون نقص سكر الدم (انخفاض مستويات السكر في الدم) خطيرًا جدًا. إذا حدث لديك انخفاض أكثر مما يجب في مستوى السكر في الدم فقد تفقد الوعي. قد يؤدي نقص سكر الدم إلى تلف خلايا المخ كما قد يكون مهددًا للحياة. إذا كنت تُعاني من أعراض انخفاض السكر بالدم، فاتخذ الإجراءات اللازمة لزيادة مستوى السكر في الدم على الفور.</p><p dir="RTL">اتصل بطبيبك على الفور، إذا عانيت من الأعراض التالية:</p><p dir="RTL">تفاعلات واسعة النطاق بالجلد (طفح جلدي وحكة في جميع أنحاء الجسم)، تورم شديد بالجلد أو الأغشية المخاطية (وذمة وعائية)، ضيق بالتنفس، هبوط في ضغط الدم مع تسارع ضربات القلب وتعرُّق. قد تكون هذه الأعراض تفاعلات حساسية شديدة تجاه الأنسولين وقد تكون مُهددة للحياة.</p><p dir="RTL">الآثار الجانبية الشائعة جدًا التي تم الإبلاغ عنها</p><p dir="RTL">(لوحظت في أكثر من مريض واحد من كل 10 مرضى)</p><p dir="RTL">* نقص سكر الدم</p><p dir="RTL">مثل جميع علاجات الأنسولين، تكون أكثر الأعراض الجانبية شيوعًا هي نقص سكر الدم.</p><p dir="RTL">نقص سكر الدم (انخفاض نسبة السكر في الدم) يعني أنه لا يوجد هناك ما يكفي من السكر في الدم. لمزيد من المعلومات حول الآثار الجانبية لانخفاض نسبة سكر الدم أو ارتفاعها، انظر الإطار في نهاية هذه النشرة.</p><p dir="RTL">الأعراض الجانبية الشائعة التي تم الإبلاغ عنها</p><p dir="RTL">(لوحظت في أكثر من مريض واحد من كل 100 مريض وأقل من مريض واحد من كل 10 مرضى)</p><p dir="RTL">* تغيرات بالجلد في موضع الحقن (ضمور الأنسجة الدهنية)</p><p dir="RTL">إذا قمت بحقن الأنسولين كثيرًا في نفس موضع الحقن، فقد تنكمش الأنسجة الدهنية الموجودة أسفل الجلد في هذا الموضع أو تصبح سميكة. قد يزيد سمك الأنسجة الدهنية في 1 إلى 2% من المرضى بينما نادرًا ما تنكمش. قد لا يعمل الأنسولين الذي تقوم بحقنه في هذا الموضع بشكل جيد جدًا. قد يساعد تغيير موضع الحقن عند كل عملية حقن في الوقاية من هذه التغيرات في الجلد.</p><p dir="RTL">* تفاعلات جلدية وحساسية</p><p dir="RTL">قد يُعاني 3 إلى 4% من المرضى من تفاعلات في موضع الحقن (مثل احمرار، ألم شديد وغير معتاد عند الحقن، حكة، شرى [ارتكاريا]، تورم أو التهاب). كما أنها يمكن أن تنتشر حول موضع الحقن. تزول معظم التفاعلات الطفيفة تجاه الأنسولين عادةً في غضون بضعة أيام إلى بضعة أسابيع.</p><p dir="RTL">الأعراض الجانبية النادرة التي تم الإبلاغ عنها (لوحظت في أكثر من مريض واحد من كل 10.000 وأقل من مريض واحد من كل 1000 مريض).</p><p dir="RTL">* تفاعلات حساسية شديدة تجاه الأنسولين</p><p dir="RTL">قد تشمل الأعراض المصاحبة تفاعلات واسعة النطاق بالجلد (طلح جلدي وحكة في جميع أنحاء الجسم)، تورم شديد بالجلد أو الأغشية المخاطية (وذمة وعائية)، ضيق بالتنفس، هبوط في ضغط الدم مع تسارع ضربات القلب وتعرُّق. قد تكون هذه الأعراض تفاعلات حساسية شديدة تجاه الأنسولين وقد تكون مُهددة للحياة.</p><p dir="RTL">* تفاعلات بالعين</p><p dir="RTL">قد يؤثر التغير الملحوظ (التحسن أو التفاقم) في نسبة التحكم في سكر الدم على رؤيته بشكل مؤقت. إذا كنت تُعاني من اعتلال الشبكية المنتشر (مرض يصيب العين مرتبط بمرض السكري) فقد تؤدي نوبات نقص سكر الدم الشديدة إلى فقدان مؤقت للرؤية.</p><p dir="RTL">تشمل الأعراض الجانبية الأخرى ما يلي:</p><p dir="RTL">يمكن أن يؤدي العلاج بالأنسولين إلى إفراز الجسم أجسام مضادة للأنسولين (المواد التي تعمل ضد الأنسولين). نادرًا، قد يتطلب هذا تغييرًا في جرعة الأنسولين الخاصة بك.</p><p dir="RTL">في حالات نادرة، قد يؤدي أيضًا العلاج بالأنسولين إلى تراكم مؤقت للماء في الجسم، مع تورم في السابقين والكاحلين.</p><p dir="RTL">في حالات نادرة جدًا، قد يحدث اضطراب بحاسة التذوق (اضطرابات التذوق) وآلام بالعضلات (ألم عضلي).</p><p dir="RTL">المرضى من الأطفال</p><p dir="RTL">بوجه عام، تكون الأعراض الجانبية التي لوحظت في المرضى بعمر 18 عامًا أو أقل مماثلة للأعراض التي تمت ملاحظتها في البالغين.</p><p dir="RTL">تم الإبلاغ عن شكاوى من حدوث تفاعلات في موضع الحقن وتفاعلات جلدية بشكل أكثر تكرارًا نسبيًا في المرضى بعمر 18 عامًا أو أقل منها في المرضى من البالغين.</p><p dir="RTL">لا تتوافر بيانات أمان خاصة بالدراسة السريرية في المرضى الأقل من 6 أعوام.</p><p dir="RTL">أبلغ الطبيب أو الصيدلي الخاص بك إذا لاحظت أيّ من الأعراض الجانبية المُدرّجة أعلاه، أو أي أعراض أخرى غير مرغوبة أو غير مُتوقّعة، للوقاية من التفاعلات الخطيرة، تحدث إلى أحد الأطباء على الفور إذا أصبح أي من الأعراض الجانبية شديدًا، أو حدث بشكل مفاجئ أو ساء سريعًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيدًا عن متناول ورؤية الأطفال.</p><p dir="RTL">لا تستخدم فيفارو بعد تاريخ انتهاء الصلاحية المدون على العبوة أو على الملصق الخاص بالقلم. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">الأقلام التي ليس قيد الاستخدام، تحفظ في الثلاجة (2 - 8 درجة مئوية). لا تجمد. لا تضع قلم فيفارو بالقرب من حجرة التجميد أو أكياس تجميد.</p><p dir="RTL">يحفظ القلم المعبأ مسبقًا في العبوة الخارجية للحماية من الضوء.</p><p dir="RTL">الأقلام قيد الاستخدام، يمكن تخزين الأقلام المعبأة مسبقًا قيد الاستخدام أو المحمولة بصفة احتياطية لمدة أقصاها 4 أسابيع في درجة حرارة لا تتجاوز 25 درجة مئوية بعيدًا عن الحرارة المباشرة أو الضوء المباشر. يجب عدم تخزين القلم قيد الاستخدام في الثلاجة. لا تستخدمه بعد هذه الفترة الزمنية.</p><p dir="RTL">يجب عدم التخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلة. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد تلك الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- المادة الفعالة هي أنسولين من النوع &quot;جلارجين&quot;.</p><p dir="RTL">يحتوي كل مللي لتر من المحلول على 100 وحدة من المادة الفعّالة أنسولين &quot;جلارجين&quot;.</p><p dir="RTL">- المكونات الأخرى لفيفارو هي: كلوريد الزنك، م - كريسول، جليسيرول، هيروكسيد الصوديوم، حامض الهيدروكلوريك وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">فيفارو 100 وحدة / مللي لتر محلول للحقن في قلم معبأ مسبقًا</p><p dir="RTL">يحتوي كل قلم على 3 مللي لتر محلول (300 وحدة).</p><p dir="RTL">تحتوي العبوة على 5 أقلام</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ساجا الصيدلانية</p><p dir="RTL">صنع بواسطة</p><p dir="RTL">سانوفي أفنتيس دويتشلاند د - 65926 فرانكفورت، ألمانيا</p><p dir="RTL">لصالح الشركة العربية السعودية اليابانية للمنتجات الصيدلانية (ساجا)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ديسمبر/ 2015
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vivaro 100 units/ml soluton for injecton in a pre-filled pen
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml contains 100 units insulin glargine (equivalent to 3.64 mg).
Each pen contains 3 ml of soluton for injecton, equivalent to 300 units.
Insulin glargine is produced by recombinant DNA technology in Escherichia coli.
For a full list of excipients, see secton 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection.
Clear colourless solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For the treatment of adults, adolescents and children of 6 years or above with diabetes<br />mellitus, where<br />treatment with insulin is required.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Vivaro contains insulin glargine, an insulin analogue, and has a prolonged duration of action.<br />Vivaro should be administered once daily at any time but at the same time each day.<br />The Vivaro dose regimen (dose and timing) should be individually adjusted. In patients with<br />type 2 diabetes mellitus, Vivaro can also be given together with orally active antidiabetic<br />medicinal products.<br />The potency of this medicinal product is stated in units. These units are exclusive to Vivaro and<br />are not the same as IU or the units used to express the potency of other insulin analogues. (see<br />secton 5.1).<br />Elderly populaton (&ge; 65 years old)<br />In the elderly, progressive deterioration of renal function may lead to a steady decrease in<br />insulin requirements.<br />Renal impairment<br />In patients with renal impairment, insulin requirements may be diminished due to reduced<br />insulin metabolism.<br />Hepatic impairment<br />In patients with hepatic impairment, insulin requirements may be diminished due to reduced<br />capacity for gluconeogenesis and reduced insulin metabolism.<br />Paediatric population<br />Safety and efficacy of Vivaro have been established in adolescents and children of 6 years and<br />above.<br />In children, efficacy and safety of Vivaro have only been assessed when given in the evening.<br />Due to limited experience on the efficacy and safety of Vivaro in children below the age of 6<br />years, Vivaro should only be used in this age group under careful medical supervision.<br />Transition from other insulins to Vivaro<br />When changing from a treatment regimen with an intermediate or long-acting insulin to a<br />regimen with Vivaro, a change of the dose of the basal insulin may be required and the<br />concomitant antidiabetic treatment may need to be adjusted (dose and timing of additional<br />regular insulins or fastacting insulin analogues or the dose of oral antidiabetic medicinal<br />products). To reduce the risk of nocturnal and early morning hypoglycaemia, patients who are<br />changing their basal insulin regimen from a twice daily NPH insulin to a once daily regimen with<br />Vivaro should reduce their daily dose of basal insulin by 20-30 % during the frst weeks of<br />treatment. During the first weeks the reduction should, at least partially, be compensated by an<br />increase in mealtime insulin, after this period the regimen should be adjusted individually.<br />As with other insulin analogues, patients with high insulin doses because of antibodies to<br />human insulin may experience an improved insulin response with Vivaro.<br />Close metabolic monitoring is recommended during the transition and in the initial weeks<br />thereafter. With improved metabolic control and resulting increase in insulin sensitivity a<br />further adjustment in dose regimen may become necessary. Dose adjustment may also be<br />required, for example, if the patient&#39;s weight or life-style changes, change of timing of insulin<br />dose or other circumstances arise that increase susceptibility to hypo-or hyperglycaemia (see<br />secton 4.4).<br />Method of administration<br />Vivaro is administered subcutaneously.<br />Vivaro should not be administered intravenously. The prolonged duration of action of Vivaro is<br />dependent on its injection into subcutaneous tissue. Intravenous administration of the usual<br />subcutaneous dose could result in severe hypoglycaemia.<br />There are no clinically relevant differences in serum insulin or glucose levels after abdominal,<br />deltoid or thigh administration of Vivaro. Injection sites must be rotated within a given injection<br />area from one injection to the next.<br />Vivaro must not be mixed with any other insulin or diluted. Mixing or diluting can change its<br />time/action profile and mixing can cause precipitation.<br />Before using Vivaro Pen, the Instructions for Use included in the Package Leaflet must be read<br />carefully (see secton 6.6).<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vivaro is not the insulin of choice for the treatment of diabetic ketoacidosis. Instead, regular<br />insulin administered intravenously is recommended in such cases.<br />In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the<br />patient&#39;s adherence to the prescribed treatment regimen, injection sites and proper injection<br />technique and all other relevant factors must be reviewed before dose adjustment is<br />considered.<br />Transferring a patient to another type or brand of insulin should be done under strict medical<br />supervision. Changes in strength, brand (manufacturer), type (regular, NPH, lente, long-acting,<br />etc.), origin (animal, human, human insulin analogue) and/or method of manufacture may<br />result in the need for a change in dose.<br />Insulin administration may cause insulin antibodies to form. In rare cases, the presence of such<br />insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency<br />to hyper- or hypoglycaemia. (see secton 4.8)<br />Hypoglycaemia<br />The time of occurrence of hypoglycaemia depends on the action profile of the insulins used and<br />may, therefore, change when the treatment regimen is changed. Due to more sustained basal<br />insulin supply with Vivaro, less nocturnal but more early morning hypoglycaemia can be<br />expected.<br />Particular caution should be exercised, and intensified blood glucose monitoring is advisable in<br />patients in whom hypoglycaemic episodes might be of particular clinical relevance, such as in<br />patients with significant stenoses of the coronary arteries or of the blood vessels supplying the<br />brain (risk of cardiac or cerebral complications of hypoglycaemia) as well as in patients with<br />proliferative retinopathy, particularly if not treated with photocoagulation (risk of transient<br />amaurosis following hypoglycaemia).<br />Patients should be aware of circumstances where warning symptoms of hypoglycaemia are<br />diminished. The warning symptoms of hypoglycaemia may be changed, be less pronounced or<br />be absent in certain risk groups. These include patients:<br />- in whom glycaemic control is markedly improved,<br />- in whom hypoglycaemia develops gradually,<br />- who are elderly,<br />- after transfer from animal insulin to human insulin,<br />- in whom an autonomic neuropathy is present,<br />- with a long history of diabetes,<br />- suffering from a psychiatric illness,<br />- receiving concurrent treatment with certain other medicinal products (see secton 4.5).<br />Such situations may result in severe hypoglycaemia (and possibly loss of consciousness) prior to<br />the patient&#39;s awareness of hypoglycaemia.<br />The prolonged effect of subcutaneous insulin glargine may delay recovery from hypoglycaemia.<br />If normal or decreased values for glycated haemoglobin are noted, the possibility of recurrent,<br />unrecognised (especially nocturnal) episodes of hypoglycaemia must be considered. Adherence<br />of the patient to the dose and dietary regimen, correct insulin administration and awareness of<br />hypoglycaemia symptoms are essential to reduce the risk of hypoglycaemia. Factors increasing<br />the susceptibility to hypoglycaemia require particularly close monitoring and may necessitate<br />dose adjustment. These include:<br />- change in the injection area,<br />- improved insulin sensitivity (e.g., by removal of stress factors),<br />- unaccustomed, increased or prolonged physical activity,<br />- intercurrent illness (e.g. vomiting, diarrhoea),<br />- inadequate food intake,<br />- missed meals,<br />- alcohol consumption,<br />- certain uncompensated endocrine disorders, (e.g. in hypothyroidism and in anterior pituitary<br />or adrenocortical insufficiency),<br />- concomitant treatment with certain other medicinal products.<br />Intercurrent illness<br />Intercurrent illness requires intensified metabolic monitoring. In many cases urine tests for<br />ketones are indicated, and often it is necessary to adjust the insulin dose. The insulin<br />requirement is often increased. Patents with type 1 diabetes must contnue to consume at<br />least a small amount of carbohydrates on a regular basis; even if they are able to eat only little<br />or no food, or are vomiting etc. and they must never omit insulin entirely.<br />Handling of the pen Before using Vivaro Pen, the Instructions for Use included in the Package<br />Leaflet must be read carefully.<br />Vivaro Pen has to be used as recommended in these Instructons for Use (see secton 6.6).<br />Medication errors<br />Medication errors have been reported in which other insulins, particularly short-acting insulins,<br />have been accidentally administered instead of insulin glargine. Insulin label must always be<br />checked before each injection to avoid medication errors between insulin glargine and other<br />insulins.<br />Combination of Vivaro with pioglitazone<br />Cases of cardiac failure have been reported when pioglitazone was used in combination with<br />insulin, especially in patients with risk factors for development of cardiac heart failure. This<br />should be kept in mind if treatment with the combination of pioglitazone and Vivaro is<br />considered. If the combination is used, patients should be observed for signs and symptoms of<br />heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration<br />in cardiac symptoms occurs.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A number of substances affect glucose metabolism and may require dose adjustment of insulin<br />glargine.<br />Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to<br />hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme<br />(ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors,<br />pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics.<br />Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol,<br />diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens, phenothiazine<br />derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline],<br />salbutamol, terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g.<br />clozapine and olanzapine) and protease inhibitors.<br />Beta-blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the bloodglucoselowering effect of insulin. Pentamidine may cause hypoglycaemia, which may<br />sometimes be followed by hyperglycaemia.<br />In addition, under the influence of sympatholytic medicinal products such as beta-blockers,<br />clonidine, guanethidine and reserpine, the signs of adrenergic counter-regulation may be<br />reduced or absent.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy category C</p><p>For insulin glargine no clinical data on exposed pregnancies from controlled clinical trials are<br />available. A moderate amount of data on pregnant women (between 300-1000 pregnancy<br />outcomes) exposed to marketed insulin glargine indicate no adverse effects of insulin glargine<br />on pregnancy and no malformative nor feto/neonatal toxicity of insulin glargine.<br />Animal data do not indicate reproductive toxicity.<br />The use of Vivaro may be considered during pregnancy, if necessary.<br />It is essential for patients with pre-existing or gestational diabetes to maintain good metabolic<br />control throughout pregnancy. Insulin requirements may decrease during the first trimester<br />and generally increase during the second and third trimesters. Immediately after delivery,<br />insulin requirements decline rapidly (increased risk of hypoglycaemia). Careful monitoring of<br />glucose control is essential.<br />Breastfeeding<br />It is unknown whether insulin glargine is excreted in human milk. No metabolic effects of<br />ingested insulin glargine on the breastfed newborn/infant are anticipated since insulin glargine<br />as a peptide is digested into aminoacids in the human gastrointestinal tract.<br />Breastfeeding women may require adjustments in insulin dose and diet.<br />Fertility<br />Animal studies do not indicate direct harmful effects with respect to fertility.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The patient&#39;s ability to concentrate and react may be impaired as a result of hypoglycaemia or<br />hyperglycaemia or, for example, as a result of visual impairment. This may constitute a risk in<br />situations where these abilities are of special importance (e.g. driving a car or operating<br />machines).<br />Patients should be advised to take precautions to avoid hypoglycaemia whilst driving. This is<br />particularly important in those who have reduced or absent awareness of the warning<br />symptoms of hypoglycaemia or have frequent episodes of hypoglycaemia. It should be<br />considered whether it is advisable to drive or operate machines in these circumstances.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypoglycaemia, in general the most frequent adverse reaction of insulin therapy, may occur if<br />the insulin dose is too high in relation to the insulin requirement.<br />The following related adverse reactions from clinical investigations are listed below by system<br />organ class and in order of decreasing incidence (very common: &ge; 1/10; common: &ge; 1/100 to &lt;<br />1/10; uncommon: &ge; 1/1,000 to &lt; 1/100; rare: &ge; 1/10,000 to &lt; 1/1,000; very rare: &lt; 1/10,000).<br />Within each frequency grouping, adverse reactions are presented in order of decreasing<br />seriousness.<br /><img alt="" width="495" height="340" src="data:image/png;base64,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" /></p><p>Metabolism and nutrition disorders<br />Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.<br />Prolonged or severe hypoglycaemic episodes may be life-threatening.<br />In many patients, the signs and symptoms of neuroglycopenia are preceded by signs of<br />adrenergic counter-regulation. Generally, the greater and more rapid the decline in blood<br />glucose, the more marked is the phenomenon of counter-regulation and its symptoms.<br />Immune system disorders Immediate-type allergic reactions to insulin are rare. Such reactions<br />to insulin (including insulin glargine) or the excipients may, for example, be associated with<br />generalised skin reactions, angiooedema, bronchospasm, hypotension and shock, and may be<br />life-threatening.<br />Insulin administration may cause insulin antibodies to form. In clinical studies, antibodies that<br />crossreact with human insulin and insulin glargine were observed with the same frequency in<br />both NPHinsulin and insulin glargine treatment groups. In rare cases, the presence of such<br />insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency<br />to hyper- or hypoglycaemia.<br />Eyes disorders<br />A marked change in glycaemic control may cause temporary visual impairment, due to<br />temporary alteration in the turgidity and refractive index of the lens.<br />Long-term improved glycaemic control decreases the risk of progression of diabetic<br />retinopathy.<br />However, intensification of insulin therapy with abrupt improvement in glycaemic control may<br />be associated with temporary worsening of diabetic retinopathy. In patients with proliferative<br />retinopathy, particularly if not treated with photocoagulation, severe hypoglycaemic episodes<br />may result in transient amaurosis.<br />Skin and subcutaneous tissue disorders<br />As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin<br />absorption. Continuous rotation of the injection site within the given injection area may help to<br />reduce or prevent these reactions.<br />General disorders and administration site conditions<br />Injection site reactions include redness, pain, itching, hives, swelling, or inflammation. Most<br />minor reactions to insulins at the injection site usually resolve in a few days to a few weeks.<br />Rarely, insulin may cause sodium retention and oedema particularly if previously poor<br />metabolic control is improved by intensified insulin therapy.<br />Paediatric population<br />In general, the safety profle for children and adolescents (&le; 18 years of age) is similar to the<br />safety profile for adults.<br />The adverse reaction reports received from post marketing surveillance included relatively<br />more frequent injection site reactions (injection site pain, injection site reaction) and skin<br />reactons (rash, urtcaria) in children and adolescents (&le; 18 years of age) than in adults.<br />No clinical study safety data are available in children below 6 years of age.<br /><img alt="" width="506" height="131" src="data:image/png;base64,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" /></p><p><img alt="" width="467" height="41" src="data:image/png;base64,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" /></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms<br />Insulin overdose may lead to severe and sometimes long-term and life-threatening<br />hypoglycaemia.<br />Management<br />Mild episodes of hypoglycaemia can usually be treated with oral carbohydrates. Adjustments in<br />dose of the medicinal product, meal patterns, or physical activity may be needed.<br />More severe episodes with coma, seizure, or neurologic impairment may be treated with<br />intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained<br />carbohydrate intake and observation may be necessary because hypoglycaemia may recur after<br />apparent clinical recovery.<br />&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes. Insulins and analogues for injection, longacting.<br />ATC Code: A10A E04.<br />Insulin glargine is a human insulin analogue designed to have a low solubility at neutral pH. It is<br />completely soluble at the acidic pH of the Vivaro injecton soluton (pH 4). Afer injecton into<br />the subcutaneous tissue, the acidic solution is neutralised leading to formation of microprecipitates from which small amounts of insulin glargine are continuously released, providing a<br />smooth, peakless, predictable concentration/time profile with a prolonged duration of action.<br />Insulin receptor binding: Insulin glargine is very similar to human insulin with respect to insulin<br />receptor binding kinetics. It can, therefore, be considered to mediate the same type of effect<br />via the insulin receptor as insulin.<br />The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism.<br />Insulin and its analogues lower blood glucose levels by stimulating peripheral glucose uptake,<br />especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin<br />inhibits lipolysis in the adipocyte, inhibits proteolysis and enhances protein synthesis.<br />In clinical pharmacology studies, intravenous insulin glargine and human insulin have been<br />shown to be equipotent when given at the same doses. As with all insulins, the time course of<br />action of insulin glargine may be affected by physical activity and other variables.<br />In euglycaemic clamp studies in healthy subjects or in patents with type 1 diabetes, the onset<br />of action of subcutaneous insulin glargine was slower than with human NPH insulin, its effect<br />profile was smooth and peakless, and the duration of its effect was prolonged.<br />:The following graph shows the results from a study in patients</p><p><img alt="" width="510" height="319" src="data:image/png;base64,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" /></p><p>The longer duration of action of subcutaneous insulin glargine is directly related to its slower<br />rate of absorption and supports once daily administration. The time course of action of insulin<br />and insulin analogues such as insulin glargine may vary considerably in different individuals or<br />within the same individual.<br />In a clinical study, symptoms of hypoglycaemia or counter-regulatory hormone responses were<br />similar after intravenous insulin glargine and human insulin both in healthy volunteers and<br />patients with type 1 diabetes.<br />Effects of insulin glargine (once daily) on diabetic retinopathy were evaluated in an open-label 5<br />year<br />NPH-controlled study (NPH given bid) in 1024 type 2 diabetc patents in which progression of<br />retnopathy by 3 or more steps on the Early Treatment Diabetc Retnopathy Study (ETDRS)<br />scale was investigated by fundus photography. No significant difference was seen in the<br />progression of diabetic retinopathy when insulin glargine was compared to NPH insulin.<br />aediatric population<br />In a randomised, controlled clinical study, paediatric patents (age range 6 to 15 years) with<br />type 1 diabetes (n = 349) were treated for 28 weeks with a basal-bolus insulin regimen where<br />regular human insulin was used before each meal. Insulin glargine was administered once daily<br />at bedtime and NPH human insulin was administered once or twice daily. Similar effects on<br />glycohemoglobin and the incidence of symptomatic hypoglycemia were observed in both<br />treatment groups, however fasting plasma glucose decreased more from baseline in the insulin<br />glargine group than in the NPH group.<br />There was less severe hypoglycaemia in the insulin glargine group as well. One hundred forty<br />three of the patients treated with insulin glargine in this study continued treatment with insulin<br />glargine in an uncontrolled extension study with mean duration of follow-up of 2 years. No new<br />safety signals were seen during this extended treatment with insulin glargine.<br />A crossover study comparing insulin glargine plus lispro insulin to NPH plus regular human<br />insulin (each treatment administered for 16 weeks in random order) in 26 adolescent type 1<br />diabetic patients aged 12 to 18 years was also performed. As in the paediatric study described<br />above, fasting plasma glucose reduction from baseline was greater in the insulin glargine group<br />than in the NPH group.<br />HbA1c changes from baseline were similar between treatment groups; however blood glucose<br />values recorded overnight were significantly higher in the insulin glargine/ lispro group than the<br />NPH/regular group, with a mean nadir of 5.4 mM vs 4.1 mM. Correspondingly, the incidences of<br />nocturnal hypoglycaemia were 32 % in the insulin glargine / lispro group vs 52 % in the NPH /<br />regular group.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In healthy subjects and diabetic patients, insulin serum concentrations indicated a slower and<br />much more prolonged absorption and showed a lack of a peak after subcutaneous injection of<br />insulin glargine in comparison to human NPH insulin. Concentrations were thus consistent with<br />the time profile of the pharmacodynamic activity of insulin glargine. The graph above shows the<br />activity profiles over time of insulin glargine and NPH insulin.<br />Insulin glargine injected once daily will reach steady state levels in 2-4 days afer the frst dose.<br />When given intravenously the elimination half-life of insulin glargine and human insulin were<br />comparable.<br />In man, insulin glargine is partly degraded in the subcutaneous tissue at the carboxyl terminus<br />of the<br />Beta chain with formaton of the actve metabolites 21A-Gly-insulin and 21A -Gly-des-30B-Thrinsulin.<br />Unchanged insulin glargine and degradation products are also present in the plasma.<br />In clinical studies, subgroup analyses based on age and gender did not indicate any difference in<br />safety and efficacy in insulin glargine-treated patients compared to the entire study population.<br />Paediatric population<br />No specific pharmacokinetic study in children or adolescents was conducted.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety<br />pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to<br />reproduction.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zinc chloride<br />m-cresol<br />glycerol 57<br />hydrochloric acid<br />sodium hydroxide<br />water for injections.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
Shelf life after first use of the pen
The medicinal product may be stored for a maximum of 4 weeks not above 25°C and away from
direct heat or direct light. Pens in use must not be stored in the refrigerator. The pen cap must
be put back on the pen after each injection in order to protect from light.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not in-use pens<br />Store in a refrigerator (2&deg;C-8&deg;C).<br />Do not freeze. Do not put Vivaro next to the freezer compartment or a freezer pack.<br />Keep the pre-filled pen in the outer carton in order to protect from light.<br />In use pens<br />For storage precautons, see secton 6.3.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>3 ml soluton in a cartridge (type 1 colourless glass) with a black plunger (bromobutyl rubber)<br />and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and<br />bromobutyl rubber).The cartridge is sealed in a disposable pen injector. Needles are not<br />included in the pack.<br />Packs of 1, 3, 4, 5, 6, 8, 9 and 10 pens are available. Not all pack sizes may be marketed.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before frst use, the pen must be stored at room temperature for 1 to 2 hours.<br />Inspect the cartridge before use. It must only be used if the solution is clear, colourless, with no<br />solid particles visible, and if it is of water-like consistency. Since Vivaro is a solution, it does not<br />require resuspension before use.<br />Vivaro must not be mixed with any other insulin or diluted. Mixing or diluting can change its<br />time/action profile and mixing can cause precipitation.<br />Empty pens must never be reused and must be properly discarded.<br />To prevent the possible transmission of disease, each pen must be used by one patient only.<br />Insulin label must always be checked before each injection to avoid medication errors between<br />insulin glargine and other insulins. (see secton 4.4)<br />Handling of the pen<br />The patient should be advised to read the instructions for use included in the package leaflet<br />carefully before using Vivaro Pen.<br /><img src="data:image/png;base64,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" alt="" width="507" height="146" vspace="0" hspace="0" border="0" style="width:507px;height:146px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>Important information for use of Vivaro Pen:<br /> Before each use, a new needle must always be carefully attached and a safety test must be<br />performed. Only needles that are compatible for use with Vivaro Pen must be used.<br /> Special caution must be taken to avoid accidental needle injury and transmission of infection.<br /> Vivaro Pen must never be used if it is damaged or if the patient is not sure if it is working<br />properly.<br /> The patient must always have a spare Vivaro Pen available in case the Vivaro Pen is lost or<br />damaged.<br />Storage Instructions<br />Please check secton 6.4 of this SPC for instructons on how to store Vivaro Pen.<br />If Vivaro Pen is in cool storage, it should be taken out 1 to 2 hours before injecton to allow it to<br />warm up. Cold insulin is more painful to inject.<br />The used Vivaro Pen must be discarded as required by your local authorities.<br />Maintenance<br />Vivaro Pen has to be protected from dust and dirt.<br />The outside of the Vivaro Pen can be cleaned by wiping it with a damp cloth.<br />The pen must not be soaked, washed or lubricated as this may damage it.<br />Vivaro Pen is designed to work accurately and safely. It should be handled with care. The<br />patient should avoid situations where Vivaro Pen may be damaged. If the patient is concerned<br />that the Vivaro Pen may be damaged, he must use a new one.<br />Step 1. Check the Insulin<br />The label on the pen should be checked to make sure it contains the correct insulin. The Vivaro<br />Vivaro Pen is grey with a purple injection button. After removing the pen cap, the appearance<br />of insulin should also be checked: the insulin solution must be clear, colorless, with no solid<br />particles visible, and must have a water-like consistency.<br />Step 2. Atach the needle<br />Only needles that are compatible for use with Vivaro Pen should be used.<br />A new sterile needle will be always used for each injection. After removing the cap, the needle<br />should be carefully attached straight onto the pen.<br />Step 3. Perform a safety test<br />Prior to each injection a safety test has to be performed to ensure that pen and needle work<br />properly and to remove air bubbles.<br />A dose of 2 units has to be selected.<br />The outer and inner needle caps should be removed.<br />While holding the pen with the needle pointing upwards, the insulin reservoir should be tapped<br />gently with the finger so that any air bubbles rise up towards the needle<br />Then the injection button should be pressed in completely.<br />If insulin has been expelled through the needle tip, then the pen and the needle are working<br />properly. If no insulin appears at the needle tp, step 3 should be repeated untl insulin appears<br />at the needle tip.<br />Step 4. Select the dose<br />The dose can be set in steps of 1 unit, from a minimum of 1 unit to a maximum of 80 units. If a<br />dose greater than 80 units is required, it should be given as two or more injectons.<br />The dose window must show &ldquo;0&rdquo; following the safety test. The dose can then be selected.<br />Step 5. Inject the dose<br />The patient should be informed on the injection technique by his health care professional.<br />The needle should be inserted into the skin.<br />The injection button should be pressed in completely. Then the injection button should be held<br />down 10 seconds before withdrawing the needle. This ensures that the full dose of insulin has<br />been injected.<br />Step 6. Remove and discard the needle<br />The needle should always be removed after each injection and discarded. This helps prevent<br />contamination and/or infection, entry of air into the insulin reservoir and leakage of insulin.<br />Needles must not be reused.<br />Special caution must be taken when removing and disposing the needle. Recommended safety<br />measures for removal and disposal of needles must be followed in order to reduce the risk of<br />accidental needle injury and transmission of infectious diseases.<br />The pen cap should be replaced on the pen.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SAJA Pharmaceuticals
Saudi Arabian Japanese pharmaceutical company limited
Jeddah – Saudi Arabia
Under license from
Sanofi-Aventis Deutschland, Germany
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dec-2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>